Cargando…

Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States

Although the Friedewald method has been used as the clinical standard to estimate low-density lipoprotein cholesterol (LDL-C) levels, a novel method with better accuracy was suggested and is now being adopted in real practice. We investigated the effect of this novel method on determining the eligib...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Doosup, Bohra, Chandrashekar, Kongpakpaisarn, Kullatham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944524/
https://www.ncbi.nlm.nih.gov/pubmed/29703063
http://dx.doi.org/10.1097/MD.0000000000010612
_version_ 1783321845282373632
author Shin, Doosup
Bohra, Chandrashekar
Kongpakpaisarn, Kullatham
author_facet Shin, Doosup
Bohra, Chandrashekar
Kongpakpaisarn, Kullatham
author_sort Shin, Doosup
collection PubMed
description Although the Friedewald method has been used as the clinical standard to estimate low-density lipoprotein cholesterol (LDL-C) levels, a novel method with better accuracy was suggested and is now being adopted in real practice. We investigated the effect of this novel method on determining the eligibility for statin treatment for primary prevention in the United States. In this cross-sectional study, we determined the discordance in the statin-eligible population for primary prevention according to the 2 different LDL-C estimating methods based on the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Using data from the National Health and Nutrition Examination Survey 2005–2014, we included 5302 nationally representative US adults aged between 40 and 75 years without history of atherosclerotic cardiovascular disease (ASCVD). Sampling weights were used in all statistical analyses to account for complex sampling design and nonresponse. If the Friedewald method is replaced by the novel method for analysis of the fasting samples, 0.2% (95% confidence interval [CI], 0.0–0.8) and 0.4% (95% CI, 0.3–0.6) of the population would no longer be eligible or would become newly eligible for statin treatment, respectively. Among the individuals with a TG level ≥150 mg/dL and LDL-C level estimated using the Friedewald method <70 mg/dL, 11.6% (95% CI, 4.0–29.3) would become newly eligible for the statin treatment when using the novel method. The use of the novel method for estimating LDL-C instead of the Friedewald method would be associated with a small net increase in statin eligible/needed US adults for primary prevention based on the 2013 ACC/AHA guidelines. Reassessment of individuals’ statin eligibility using the novel method may be beneficial, particularly when their TG level is 150 mg/dL or higher and LDL-C(F) level is lower than 70 mg/dL.
format Online
Article
Text
id pubmed-5944524
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-59445242018-05-15 Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States Shin, Doosup Bohra, Chandrashekar Kongpakpaisarn, Kullatham Medicine (Baltimore) Research Article Although the Friedewald method has been used as the clinical standard to estimate low-density lipoprotein cholesterol (LDL-C) levels, a novel method with better accuracy was suggested and is now being adopted in real practice. We investigated the effect of this novel method on determining the eligibility for statin treatment for primary prevention in the United States. In this cross-sectional study, we determined the discordance in the statin-eligible population for primary prevention according to the 2 different LDL-C estimating methods based on the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Using data from the National Health and Nutrition Examination Survey 2005–2014, we included 5302 nationally representative US adults aged between 40 and 75 years without history of atherosclerotic cardiovascular disease (ASCVD). Sampling weights were used in all statistical analyses to account for complex sampling design and nonresponse. If the Friedewald method is replaced by the novel method for analysis of the fasting samples, 0.2% (95% confidence interval [CI], 0.0–0.8) and 0.4% (95% CI, 0.3–0.6) of the population would no longer be eligible or would become newly eligible for statin treatment, respectively. Among the individuals with a TG level ≥150 mg/dL and LDL-C level estimated using the Friedewald method <70 mg/dL, 11.6% (95% CI, 4.0–29.3) would become newly eligible for the statin treatment when using the novel method. The use of the novel method for estimating LDL-C instead of the Friedewald method would be associated with a small net increase in statin eligible/needed US adults for primary prevention based on the 2013 ACC/AHA guidelines. Reassessment of individuals’ statin eligibility using the novel method may be beneficial, particularly when their TG level is 150 mg/dL or higher and LDL-C(F) level is lower than 70 mg/dL. Wolters Kluwer Health 2018-04-27 /pmc/articles/PMC5944524/ /pubmed/29703063 http://dx.doi.org/10.1097/MD.0000000000010612 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle Research Article
Shin, Doosup
Bohra, Chandrashekar
Kongpakpaisarn, Kullatham
Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
title Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
title_full Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
title_fullStr Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
title_full_unstemmed Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
title_short Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
title_sort novel method versus the friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the united states
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944524/
https://www.ncbi.nlm.nih.gov/pubmed/29703063
http://dx.doi.org/10.1097/MD.0000000000010612
work_keys_str_mv AT shindoosup novelmethodversusthefriedewaldmethodforestimatinglowdensitylipoproteincholesterolindeterminationoftheeligibilityforstatintreatmentforprimarypreventionintheunitedstates
AT bohrachandrashekar novelmethodversusthefriedewaldmethodforestimatinglowdensitylipoproteincholesterolindeterminationoftheeligibilityforstatintreatmentforprimarypreventionintheunitedstates
AT kongpakpaisarnkullatham novelmethodversusthefriedewaldmethodforestimatinglowdensitylipoproteincholesterolindeterminationoftheeligibilityforstatintreatmentforprimarypreventionintheunitedstates